First China Pharmaceutical Group Inc (fka FCPG)

[Chargers Beat Writer]

Revenue of 33,736,682.64 USD in 3rd Qtr. for Kunming Pharmaceutical Group Co., Ltd.

I don't mean to confuse things, so I apologize if I have the wrong company. However, I think I just found the current financials for the 3rd Qtr for Kunming Pharmaceutical Group.

Kunming Pharmaceutical Group Co., Ltd.
http://finance.sina.com.cn/stock/t/20141022/010020602347.shtml

An Important Notice

1.1 Board of Directors, supervisors and directors, supervisors and senior management personnel shall guarantee the authenticity of this quarterly report, accurate, complete, and there is no false records, misleading statements or material omissions, and assume joint and several liability.

1.2 All directors attended the Board of Directors reviewed the quarterly report.

1.3 The person in charge of HE Qin, director of accounting and Wang Shao-wide accounting department (accounting officer) Zhu Youqiang guarantee financial statements quarterly report is true, accurate and complete.

1.4 The third quarterly report is unaudited.

Second, changes in key financial data and company shareholders

2.1 Key Financial Data

Unit: Currency: RMB

This reporting period

End of last year

Over the end of the reporting period the previous year change (%)

Total assets

2,922,875,251.39

2,885,839,475.35

1.28

Net assets attributable to shareholders of listed companies

1,841,760,489.85

1,757,991,412.79

4.77

Year to the end of the period

(January to September)

The beginning of the reporting period to the previous year

(January to September)

Than last year (%)

Net cash flow from operating activities

206,151,436.86

128,917,517.89

59.91

Year to the end of the period

(January to September)

The beginning of the reporting period to the previous year

(January to September)

Decrease over the previous year

(%)

Operating income

2,904,622,676.29

2,598,663,326.47

11.77

Net profit attributable to shareholders of listed companies

203,165,839.01

163,624,521.24

24.17

Net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses

174,551,637.39

159,074,110.41

9.73

Weighted average return on net assets (%)

10.93

14.37

3.44 percentage point reduction

Basic earnings per share (RMB / share)

0.5956

0.4797

24.16

Diluted earnings per share (RMB / share)

0.5956

0.4797

24.16

The total number of shareholders and top ten shareholders and the top ten tradable shareholders 2.2 cutoff of the reporting period (or tradable shareholders) holding Fact Sheet

Unit: Share

Total number of shareholders (households)

15036

The top ten shareholders

Name of shareholder

Changes in the reporting period

Closing number of shares

Percentage (%)

Number of shares held by moratorium

Pledged or frozen

Nature of shareholders

(Full name)

Shares state

Quantity

Hua Fang Pharmaceutical Co., Ltd.

0

64,250,225

18.83

0

Freeze

6,000,000

Domestic non-state-owned legal person

Yunnan Hongta Group Co., Ltd.

0

29,991,365

8.79

0

Unknown

Domestic non-state-owned legal person

China Construction Bank(4.07, 0.03, 0.74%) Co., Ltd. - Manulife TEDA efficiency optimization hybrid securities investment fund

-1,732,740

10,956,337

3.21

0

Unknown

Other

China Industrial and Commercial Bank of China(3.54, 0.02, 0.57%) - Huitianfu Growth Securities Investment Fund

-4,004,690

9,500,000

2.78

0

Unknown

Other

Yunnan Industrial Investment Holding Group Co., Ltd.

0

5,287,108

1.55

0

Unknown

State-owned corporation

China Everbright Bank(2.69, 0.04, 1.51%) Co., Ltd. - optimal mix of resources, Morgan Stanley Huaxin Securities Investment Fund

-950,007

5,210,084

1.53

0

Unknown

Other

Bank of China(2.69, 0.05, 1.89%) - Franklin Templeton Sealand potential combination Securities Investment Fund

-1,435,599

5,000,000

1.47

0

Unknown

Other

Fujian Ping

4,954,903

1.45

0

Unknown

Domestic natural person

Bank of China - Harvest Theme Selected Mixed Securities Investment Fund

4,799,863

1.41

0

Unknown

Other

China Ping An(42.05, 1.34, 3.29%) Life Insurance Company Limited - Traditional - General Insurance

-5,900,400

4,700,316

1.38

0

Unknown

Other

Top ten tradable shareholders

Name of shareholder

Hold the number of tradable shares

The type and quantity of shares

Species

Quantity

Hua Fang Pharmaceutical Co., Ltd.

64,250,225

RMB ordinary shares

64,250,225

Yunnan Hongta Group Co., Ltd.

29,991,365

RMB ordinary shares

29,991,365

China Construction Bank Corporation [microblogging] - Manulife TEDA efficiency optimization hybrid securities investment fund

10,956,337

RMB ordinary shares

10,956,337

ICBC China - Huitianfu Growth Securities Investment Fund

9,500,000

RMB ordinary shares

9,500,000

Yunnan Industrial Investment Holding Group Co., Ltd.

5,287,108

RMB ordinary shares

5,287,108

China Everbright Bank Co., Ltd. - optimal mix of resources, Morgan Stanley Huaxin Securities Investment Fund

5,210,084

RMB ordinary shares

5,210,084

Bank of China - Franklin Templeton Sealand potential combination Securities Investment Fund

5,000,000

RMB ordinary shares

5,000,000

Fujian Ping

4,954,903

RMB ordinary shares

4,954,903

Bank of China - Harvest Theme Selected Mixed Securities Investment Fund

4,799,863

RMB ordinary shares

4,799,863

China Ping [microblogging] Life Insurance Company Limited - Traditional - General Insurance

4,700,316

RMB ordinary shares

4,700,316

The shareholders' association or the concerted action

Restoration of voting rights and number of shares of preferred shareholders description

Third, the important issues

3.1 The main financial statements and financial indicators and the reasons for significant changes

v Applicable ? NA

Unit: Currency: RMB

Account Name

Issue / Closing

The previous period / early

Changes in the ratio (%)

Reasons for change

Accounts receivable

472,633,488.86

362,618,240.41

30.34

Increase customer arrears issue

Other receivables

109,757,815.75

58,032,164.72

89.13

Margin increased land issue

Other current assets

396,114,411.41

552,503,364.83

-28.31

Reduce the current investment products

Fixed assets

398,823,870.41

301,889,674.38

32.11

Construction in progress carried forward

Construction in progress

90,097,591.07

192,450,644.14

-53.18

Construction in progress carried forward

Short-term borrowings

124,500,000.00

30,000,000.00

315.00

Increase in current loans

Long-term borrowings

24,500,000.00

0

Not applicable

This issue loans increased, the period without

Other payables

264,793,661.03

170,055,987.79

55.71

With revenue growth and growth

Business tax and surcharges

19,406,021.39

14,792,894.51

31.18

With revenue growth and growth

Financial expenses

8,820,278.17

20,203,985.02

-56.34

On repayment of short-term financial interest, no issue

Impairment losses on assets

2,478,232.36

6,020,247.04

-58.84

On equity of provision for impairment, no issue

Net cash flow from operating activities

206,151,436.86 or 33,736,682.64 USD

128,917,517.89

59.91

Increase the current cash payment

Net cash flow from investing activities

-147,867,599.21

-632,378,083.72

Not applicable

The current project expenditure reduced?

Net cash flow from financing activities

85,920,732.62

509,022,840.76

-83.12

The public issuance of shares, issue no?

3.2 Company and shareholder holding more than 5% of the fulfillment of commitments

v Applicable ? NA

Commitment background

Commitment type

Commitment party

Commitment Content

Commitment of time and deadlines

Are there performance period

Implementation of the commitments

Commitments associated with refinancing

Resolve intra-industry competition

Actual control

Actual control of the issuer for the current situation with the competition in terms of the presence of artemisinin, on December 24, 2012 commitment: "The current anti-malarial Artemisia annua industry charitable industry, mainly large international pharmaceutical company Novartis, Sanofi and other monopolies, the above related parties artemisinin business achieve lower annual profit, and therefore require long-term cultivation of listed companies will contribute to make the light of historical issues, in the next five years, according to artemisinin overall market conditions, companies annua prime business development, the degree of recognition of the capital market, through asset acquisitions, restructuring and other means, to develop specific operation of the program, step by step, so as to solve the Kunming system

Artemisinin drugs in terms of competition with the industry scenario. "To solve the issuer and the actual controller of other companies in the same industry in terms of artemisinin competition, the actual controller Wang Licheng on March 22, 2013 to be adopted in the following manner in order to avoid competition: (1) will continue to remain in Kunming Pharmaceuticals(26.81, 0.14, 0.52%) existing good corporate governance structure, fully maintain independence in Kunming Pharmaceutical assets, personnel, business, institutional, financial aspects, to ensure that listed companies Kunming Pharmaceutical norms by independent operators to ensure the Kunming Pharmaceutical an independent and complete business system and independent operators the ability to directly market-oriented; (2) the actual controller will be invested at fair treatment of all enterprises, and not used as the actual control status or use of information obtained in this position, make no conducive to the issuer and the decision in favor of other companies, if the issues related to the actual controller directly intervene in specific production and business activities of enterprises, which results in a loss of the issuer, the actual controller will take the responsibility; and (3) to take positive measures to eliminate the issuer and with the competition or potential competition with the status of artemisinin-based enterprises under the control of actual control between the specific measures including, but not limited to:. a In five years, that is, before 31 December 2017, and gradually to mergers and acquisitions, restructuring and business restructuring, etc., to complete the issuer Kunming Pharmaceutical application documents issuance of A shares prospectus assets and business 1-1-131 and the actual control under the control of artemisinin-based enterprise integration between .b. assist issuers the introduction of new external strategic investors to optimize corporate governance structure c. progressively to mergers and acquisitions, restructuring and business restructuring, etc., to complete the integration of the assets and business of the issuer under artemisinin-based enterprises and the actual control between control by the above measures over the next five years, it will completely solve the issuer and the actual control under the control of artemisinin-based companies with the competition.

December 31, 2017

Are

As of this announcement, the commitment to strictly fulfill the commitments (1), (2), does not appear contrary to the case of the above commitments.

Commitments associated with refinancing

Solve the related party transactions

Controlling shareholder and actual controller


The controlling shareholder of the Company, of commitments: As the controlling shareholder of Kunming Pharmaceutical, the actual controller, will minimize and regulate related party transactions between its subsidiaries and Kunming Pharmaceutical. For unavoidable or have reasonable grounds related transactions occurred, including but not limited to, commodity trading, providing services to each other, or as a proxy, the company will strictly follow all equivalent, paid the principles of fair trade, fair trade in a market does not require the Kunming Pharmaceutical and its subsidiaries provide superior to any third party or giving third parties the conditions and in accordance with "related trading system" and other normative documents related to the articles of association and the Kunming Pharmaceutical fulfill the legal approval process and enter into related agreements / contract, timely information disclosure norms related transactions, to ensure that no damage to the legitimate interests of related party transactions by Kunming Pharmaceutical and other shareholders, to raise funds to ensure that this issue does not generate new investment projects related party transactions.

No

As of this announcement, the commitment to strictly fulfill this commitment, the commitment does not appear contrary to the above case.

Kunming Pharmaceutical Group Co., Ltd.

Chairman: HE Qin

October 21, 2014

Enter [Reuters shares it] discussion